Vijaya Diagnostic Centre Limited
Vijaya Diagnostic Centre Limited Fundamental Analysis
Vijaya Diagnostic Centre Limited (VIJAYA.NS) shows strong financial fundamentals with a PE ratio of 57.80, profit margin of 20.77%, and ROE of 20.01%. The company generates $7.7B in annual revenue with strong year-over-year growth of 24.39%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 87.4/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze VIJAYA.NS's fundamental strength across five key dimensions:
Efficiency Score
ExcellentVIJAYA.NS demonstrates superior asset utilization.
Valuation Score
WeakVIJAYA.NS trades at a premium to fair value.
Growth Score
ExcellentVIJAYA.NS delivers strong and consistent growth momentum.
Financial Health Score
ExcellentVIJAYA.NS maintains a strong and stable balance sheet.
Profitability Score
ExcellentVIJAYA.NS achieves industry-leading margins.
Key Financial Metrics
Is VIJAYA.NS Expensive or Cheap?
P/E Ratio
VIJAYA.NS trades at 57.80 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, VIJAYA.NS's PEG of 10.94 indicates potential overvaluation.
Price to Book
The market values Vijaya Diagnostic Centre Limited at 10.65 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 26.82 times EBITDA. This signals the market has high growth expectations.
How Well Does VIJAYA.NS Make Money?
Net Profit Margin
For every $100 in sales, Vijaya Diagnostic Centre Limited keeps $20.77 as profit after all expenses.
Operating Margin
Core operations generate 29.18 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $20.01 in profit for every $100 of shareholder equity.
ROA
Vijaya Diagnostic Centre Limited generates $11.46 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Vijaya Diagnostic Centre Limited produces operating cash flow of $1.39B, showing steady but balanced cash generation.
Free Cash Flow
Vijaya Diagnostic Centre Limited produces free cash flow of $453.03M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $4.41 in free cash annually.
FCF Yield
VIJAYA.NS converts 0.49% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
57.80
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
10.94
vs 25 benchmark
P/B Ratio
Price to book value ratio
10.65
vs 25 benchmark
P/S Ratio
Price to sales ratio
12.004
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.42
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.00
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.20
vs 25 benchmark
ROA
Return on assets percentage
0.11
vs 25 benchmark
ROCE
Return on capital employed
0.18
vs 25 benchmark
How VIJAYA.NS Stacks Against Its Sector Peers
| Metric | VIJAYA.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 57.80 | 28.45 | Worse (Expensive) |
| ROE | 20.01% | 763.00% | Weak |
| Net Margin | 20.77% | -45265.00% (disorted) | Strong |
| Debt/Equity | 0.42 | 0.34 | Weak (High Leverage) |
| Current Ratio | 2.00 | 2795.60 | Neutral |
| ROA | 11.46% | -16588.00% (disorted) | Strong |
VIJAYA.NS outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Vijaya Diagnostic Centre Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
99.59%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
126.96%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
109.86%
Industry Style: Defensive, Growth, Innovation
High Growth